Failure To Invest In Drug Repositioning Is Frustrating, Says EU Rare Disease Patients Group
Executive Summary
Yann Le Cam, who heads the EU network of rare disease patient organizations, is calling for innovative solutions to support the 'repositioning' of existing and new medicines that could potentially treat orphan conditions but are not developed by companies due to business considerations.
You may also be interested in...
Industry Welcomes Mandatory EU Joint Clinical Assessments For HTA
Draft proposals to improve EU-wide cooperation on health technology assessments, including mandatory joint clinical assessments, have won support from EFPIA, the European Federation of Pharmaceutical Industries and Associations.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.